Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus 2020-07-30 20:34
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP) 2020-07-29 19:30
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models 2020-05-20 19:00
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo(R) (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment 2020-05-14 19:00
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI 2020-04-30 20:00
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference 2020-04-29 04:30
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June 2020-04-28 20:00
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea 2020-04-16 18:00
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today 2020-04-06 20:30
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia 2020-03-30 21:00
INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia 2020-03-26 21:00
INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine 2020-03-12 20:00
Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800 2020-03-03 21:00
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP) 2020-02-10 19:00
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections 2020-02-03 21:00
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China 2020-01-30 19:00
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus 2020-01-24 00:26
Inovio Provides Update on Clinical Program Plans for 2020 2020-01-06 21:00
Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) 2019-11-05 21:00
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection 2019-09-17 21:00
1 2 3